VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+35.87%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$211M
AUM Growth
+$211M
(-13%)
Cap. Flow
-$93.6M
Cap. Flow
% of AUM
-44.31%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| 1 |
Delek Logistics
DKL
|
$1.51M |
| 2 |
Western Midstream Partners
WES
|
$1.18M |
| 3 |
Viper Energy
VNOM
|
$953K |
| 4 |
Marathon Petroleum
MPC
|
$839K |
| 5 |
EPR Properties
EPR
|
$814K |
Top Sells
| 1 |
Barings BDC
BBDC
|
$2.75M |
| 2 |
Prospect Capital
PSEC
|
$2.59M |
| 3 |
WhiteHorse Finance
WHF
|
$2.34M |
| 4 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$2.34M |
| 5 |
Nuveen Credit Strategies Income Fund
JQC
|
$2.27M |
Sector Composition
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Capital Southwest
CSWC
$1.27B
| $637K | 0.3% |
47,284
-116,520
| -71% | -$1.57M |
|
102
Vertex Pharmaceuticals
VRTX
$102B
| $633K | 0.3% |
2,179
-502
| -19% | -$146K |
|
103
Alnylam Pharmaceuticals
ALNY
$58.6B
| $632K | 0.3% |
4,269
-733
| -15% | -$109K |
|
104
Esperion Therapeutics
ESPR
$490M
| $632K | 0.3% |
12,310
+5,075
| +70% | +$261K |
|
|
WPG
105
DELISTED
Washington Prime Group Inc.
WPG
| $630K | 0.3% |
749,225
+296,631
| +66% | +$249K |
|
106
Halozyme
HALO
$8.75B
| $629K | 0.3% |
23,455
-7,541
| -24% | -$202K |
|
107
BioMarin Pharmaceuticals
BMRN
$11.3B
| $624K | 0.3% |
5,063
-2,274
| -31% | -$280K |
|
|
108
Nuveen Credit Strategies Income Fund
JQC
$751M
| $616K | 0.29% |
105,506
-389,391
| -79% | -$2.27M |
|
109
Ultragenyx Pharmaceutical
RARE
$3.04B
| $615K | 0.29% |
7,864
-5,910
| -43% | -$462K |
|
|
SAGE
110
DELISTED
Sage Therapeutics
SAGE
| $615K | 0.29% |
14,782
+6,710
| +83% | +$279K |
|
|
ONC
111
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $615K | 0.29% |
3,265
-78
| -2% | -$14.7K |
|
|
IMMU
112
DELISTED
Immunomedics Inc
IMMU
| $613K | 0.29% |
17,305
-92
| -0.5% | -$3.26K |
|
113
Regeneron Pharmaceuticals
REGN
$59.8B
| $612K | 0.29% |
981
-671
| -41% | -$419K |
|
114
Agios Pharmaceuticals
AGIO
$2.36B
| $607K | 0.29% |
11,354
-1,246
| -10% | -$66.6K |
|
115
Karyopharm Therapeutics
KPTI
$61.4M
| $607K | 0.29% |
32,050
-3,084
| -9% | -$58.2K |
|
116
Nektar Therapeutics
NKTR
$543M
| $605K | 0.29% |
26,122
-1,544
| -6% | -$35.8K |
|
117
Incyte
INCY
$17B
| $604K | 0.29% |
5,813
-611
| -10% | -$63.5K |
|
118
Ironwood Pharmaceuticals
IRWD
$201M
| $604K | 0.29% |
58,560
+12,557
| +27% | +$130K |
|
|
SGEN
119
DELISTED
Seagen Inc. Common Stock
SGEN
| $602K | 0.29% |
3,541
-1,627
| -31% | -$277K |
|
|
BPMC
120
DELISTED
Blueprint Medicines
BPMC
| $597K | 0.28% |
7,658
+2,822
| +58% | +$220K |
|
|
BGX
121
Blackstone Long-Short Credit Income Fund
BGX
$159M
| $592K | 0.28% |
49,128
-141,758
| -74% | -$1.71M |
|
122
Neurocrine Biosciences
NBIX
$13.5B
| $587K | 0.28% |
4,807
-515
| -10% | -$62.9K |
|
|
ALXN
123
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $580K | 0.27% |
5,166
-478
| -8% | -$53.7K |
|
124
Amgen
AMGN
$153B
| $579K | 0.27% |
2,456
-33
| -1% | -$7.78K |
|
|
BGB
125
Blackstone Strategic Credit 2027 Term Fund
BGB
$557M
| $576K | 0.27% |
50,420
-167,919
| -77% | -$1.92M |
|